Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.07)
# 2,211
Out of 4,874 analysts
55
Total ratings
32.65%
Success rate
-0.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $21.08 | +208.35% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $10.50 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $15.13 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.56 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $28.71 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.51 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $5.31 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $5.07 | +97.24% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $299.51 | - | 4 | Nov 20, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $47.29 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $56.28 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.73 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $37.95 | -36.76% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $4.85 | +9,178.35% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.34 | +4,011.60% | 1 | Mar 3, 2021 |
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $21.08
Upside: +208.35%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.50
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.13
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.56
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $28.71
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $13.51
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.31
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $5.07
Upside: +97.24%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $299.51
Upside: -
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $47.29
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $56.28
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.73
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $37.95
Upside: -36.76%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $4.85
Upside: +9,178.35%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.34
Upside: +4,011.60%